Copyright
©The Author(s) 2018.
World J Gastroenterol. Mar 28, 2018; 24(12): 1353-1360
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1353
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1353
Figure 1 Model for end-stage liver disease score after the end of antiviral treatment.
Differences in MELD score compared to baseline at A: the end of therapy; B: 12 wk after the end of treatment; C: and, 24 wk after the end of treatment. Each column indicates one patient. MELD: Model for end-stage liver disease.
- Citation: Rupp C, Hippchen T, Neuberger M, Sauer P, Pfeiffenberger J, Stremmel W, Gotthardt DN, Mehrabi A, Weiss KH. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus. World J Gastroenterol 2018; 24(12): 1353-1360
- URL: https://www.wjgnet.com/1007-9327/full/v24/i12/1353.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i12.1353